Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction

Bibliography

• FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. (1994) 151(1):54–61.
   PubMed Web of Science ®Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impotence Res. (1996) 8:47–52.
   PubMedGoogle Scholar
• BOOLELL M, GEPI-ATTEE S, GINGELL JC, ALLEN MJ: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br. J. Urol. (1996) 78(2):257–261.
   PubMedGoogle Scholar
• BURNETT AL: The impact of sildenafil on molecular science and sexual health. Eur. Urol. (2004) 46(1):9–14.
   PubMed Web of Science ®Google Scholar
• LUE TF: Erectile dysfunction. N. Engl. J. Med. (2000) 342(24):1802–1813.
   PubMed Web of Science ®Google Scholar
• ROTELLA DP: Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. (2002) 1(9):674–682.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, SALONIA A, DEHO F et al.: Pharmacological management of erectile dysfunction. BJU Int. (2003) 91(5):446–454.
   PubMed Web of Science ®Google Scholar
• WAGNER G, MONTORSI F, AUERBACH S, COLLINS M: Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J. Gerontol. A Biol. Sci. Med. Sci. (2001) 56(2):M113–M119.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, SALONIA A, DEHO F, BRIGANTI A, RIGATTI P: The ageing male and erectile dysfunction. World J. Urol. (2002) 20(1):28–35.
   PubMed Web of Science ®Google Scholar
• CARSON CC, BURNETT AL, LEVINE LA, NEHRA A: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60(2 Suppl. 2):12–27.
   PubMed Web of Science ®Google Scholar
• SEFTEL AD, SUN P, SWINDLE R: The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J. Urol. (2004) 171(6 Pt 1):2341–2345.
   Google Scholar
• RENDELL MS, RAJFER J, WICKER PA, SMITH MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA (1999) 281(5):421–426.
   PubMed Web of Science ®Google Scholar
• STUCKEY BG, JADZINSKY MN, MURPHY LJ et al.: Sildenafil citrate for treatment of erectile dysfunction in men with Type 1 diabetes: results of a randomized controlled trial. Diabetes Care (2003) 26(2):279–284.
   PubMed Web of Science ®Google Scholar
• KOPPIKER N, BOOLELL M, PRICE D: Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. Endocr. Pract. (2003) 9(1):52–63.
   PubMedGoogle Scholar
• ROUMEGUERE T, WESPES E, CARPENTIER Y, HOFFMANN P, SCHULMAN CC: Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur. Urol. (2003) 44(3):355–359.
   PubMed Web of Science ®Google Scholar
• NURNBERG HG, SEIDMAN SN, GELENBERG AJ et al.: Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology (2002) 60(2 Suppl. 2):58–66.
   Google Scholar
• ARSLAN D, ASLAN G, SIFIL A et al.: Sexual dysfunction in male patients on hemodialysis: assessment with the International Index of Erectile Function (IIEF). Int. J. Impot. Res. (2002) 14(6):539–542.
   PubMed Web of Science ®Google Scholar
• FORESTA C, CARETTA N, ROSSATO M, GAROLLA A, FERLIN A: Role of androgens in erectile function. J. Urol. (2004) 171(6 Pt 1):2358–2362, quiz 2435.
   Google Scholar
• MONTORSI F, SALONIA A, ZANONI M et al.: Counselling the patient with prostate cancer about treatment-related erectile dysfunction. Curr. Opin. Urol. (2001) 11(6):611–617.
   PubMedGoogle Scholar
• RAMOS AS, SAMSO JV: Specific aspects of erectile dysfunction in spinal cord injury. Int. J. Impot. Res. (2004) 16(Suppl. 2):S42–S45.
   Google Scholar
• GADES NM, NEHRA A, JACOBSON DJ et al. : Association between smoking and erectile dysfunction: a population-based study. Am. J. Epidemiol. (2005) 161(4):346–351.
   PubMed Web of Science ®Google Scholar
• NATALI A, MONDAINI N, LOMBARDI G, DEL POPOLO G, RIZZO M: Heavy smoking is an important risk factor for erectile dysfunction in young men. Int. J. Impot. Res. (2005) 17(3):227–230.
   PubMed Web of Science ®Google Scholar
• ESPOSITO K, GIUGLIANO F, DI PALO C et al.: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA (2004) 291(24):2978–2984.
   PubMed Web of Science ®Google Scholar
• PONHOLZER A, TEMML C, MOCK K et al.: Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur. Urol. (2005) 47(1):80–85;discussion 85–86.
   Google Scholar
• DERBY CA, MOHR BA, GOLDSTEIN I et al. : Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology (2000) 56(2):302–306.
   Google Scholar
• MATFIN G, JAWA A, FONSECA VA: Erectile dysfunction: interrelationship with the metabolic syndrome. Curr. Diab. Rep. (2005) 5(1):64–69.
   PubMedGoogle Scholar
• SOUVEREIN PC, EGBERTS AC, MEULEMAN EJ, URQUHART J, LEUFKENS HG: Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int. J. Impot. Res. (2002) 14(4):259–265.
   PubMed Web of Science ®Google Scholar
• GONZALGO ML, BROTZMAN M, TROCK BJ et al.: Clinical efficacy of sildenafil citrate and predictors of long-term response. J. Urol. (2003) 170(2 Pt 1):503–506.
   Google Scholar
• SON H, PARK K, KIM SW, PAICK JS: Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J. Androl. (2004) 6(2):117–120.
   PubMed Web of Science ®Google Scholar
• KLOTZ T, MATHERS M, KLOTZ R, SOMMER F: Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? Int. J. Impot. Res. (2005) 17(1):2–4.
   PubMed Web of Science ®Google Scholar
• EARDLEY I, BROOKS J, YATES PK, ELLIS P, BOOLELL M: Sildenafil citrate (VIAGRA): an oral treatment for erectile function with activity for up to four hours’duration. Int. J. Clin. Pract. Suppl. (1999) 102:32–34.
   PubMedGoogle Scholar
• MONCADA I, JARA J, SUBIRA D, CASTANO I, HERNANDEZ C: Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur. Urol. (2004) 46(3):357–360; discussion 360–361.
   Google Scholar
• NICHOLS DJ, MUIRHEAD GJ, HARNESS JA: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol. (2002) 53(Suppl. 1):5S–12S.
   Google Scholar
• DEVECI S, PESKIRCIOGLU L, AYGUN C et al.: Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose. Int J. Urol. (2004) 11(11):989–992.
   PubMed Web of Science ®Google Scholar
• WEBB DJ, MUIRHEAD GJ, WULFF M et al.: Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J. Am. Coll. Cardiol. (2000) 36(1):25–31.
   PubMed Web of Science ®Google Scholar
• WILNER KD, TENSFELDT TG, BARIS B et al.: Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br. J. Clin. Pharmacol. (2000) 49(Suppl. 1):15S–20S.
   Web of Science ®Google Scholar
• HYLAND R, ROE EG, JONES BC, SMITH DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br. J. Clin. Pharmacol. (2001) 51(3):239–248.
   PubMed Web of Science ®Google Scholar
• GOPAL VK, FRANCIS SH, CORBIN JD: Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur. J. Biochem. (2001) 268:3304–3312.
   PubMedGoogle Scholar
• FAGELMAN E, FAGELMAN A, SHABSIGH R: Efficacy, safety, and use of sildenafil in urologic practice. Urology (2001) 57(6):1141–1144.
   PubMed Web of Science ®Google Scholar
• CORBIN JD, FRANCIS SH: Cyclic GMP phosphodiesterase 5: target for sildenafil. J. Biol. Chem. (1999) 274:13729–13732. Thorough description of molecular characteristics of PDE5 and factors that contribute to specificity of sildenafil interaction with PDE5.
   PubMed Web of Science ®Google Scholar
• KUTHE A, MAGERT H, UCKERT S et al.: Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur. Urol. (2000) 38(1):108–114.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, CORBIN JD: Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit. Rev. Clin. Lab. Sci. (1999) 36:275–328.
   PubMed Web of Science ®Google Scholar
• LINCOLN TM, DEY N, SELLAK H: Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J. Appl. Physiol. (2001) 91(3):1421–1430.
   PubMed Web of Science ®Google Scholar
• MUNZEL T, FEIL R, MULSCH A et al.: Physiology and pathophysiology of vascular signaling controlled by guanosine 3’5’ cyclic monophosphate-dependent protein kinase [corrected]. Circulation (2003) 108(18):2172–2183.
   PubMed Web of Science ®Google Scholar
• HOFMANN F: The biology of cyclic GMP-dependent protein kinases. J. Biol. Chem. (2005) 280(1):1–4.
   PubMed Web of Science ®Google Scholar
• ROBISON GA, BUTCHER RW, SUTHERLAND EW: Cyclic AMP. Academic Press, New York, USA (1971).
   Google Scholar
• BALLARD SA, GINGELL CJ, TANG K et al.: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. (1998) 159(6):2164–2171.
   PubMed Web of Science ®Google Scholar
• CORBIN JD, FRANCIS SH: Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. (2002) 56(6):453–459.
   PubMed Web of Science ®Google Scholar
• BLOUNT MA, BEASLEY A, ZORAGHI R et al.: Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol. (2004) 66(1):144–152.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, CORBIN JD: Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr. Urol. Rep. (2003) 4(6):457–465.
   PubMedGoogle Scholar
• CORBIN JD, FRANCIS SH: Molecular biology and pharmacology of PDE-5- inhibitor therapy for erectile dysfunction. J. Androl. (2003) 24(6 Suppl.): S38–S41.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, TURKO IV, CORBIN JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. (2001) 65:1–52.
   PubMed Web of Science ®Google Scholar
• WALLIS RM, CORBIN JD, FRANCIS SH, ELLIS P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83:3–12.
   PubMed Web of Science ®Google Scholar
• LIN CS, LAU A, TU R, LUE TF: Expression of three isoforms of cGMPbinding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem. Biophys. Res. Commun. (2000) 268:628–635.
   PubMed Web of Science ®Google Scholar
• GEISELHORINGER A, WERNER M, SIGL K et al.: IRAG is essential for relaxation of receptor-triggered smooth muscle contraction by cGMP kinase. EMBO J. (2004) 23(21):4222–4231.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED, MCMURTRY MS, SONNENBERG B, ARCHER SL: The NO- K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. Adv. Exp. Med. Biol. (2003) 543:293–322.
   PubMed Web of Science ®Google Scholar
• MAURICE DH, HASLAM RJ: Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. (1990) 37(5):671–681.
   PubMed Web of Science ®Google Scholar
• DUNKERN TR, HATZELMANN A: The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal (2005) 17(3):331–339.
   PubMed Web of Science ®Google Scholar
• ZUSMAN RM, MORALES A, GLASSER DB, OSTERLOH IH: Overall cardiovascular profile of sildenafil citrate. [Review] [33 refs]. Am. J. Cardiol. (1999) 83(5A):35C-44C.
   Google Scholar
• VARDI Y, KLEIN L, NASSAR S, SPRECHER E, GRUENWALD I: Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology (2002) 59(5):747–752.
   PubMed Web of Science ®Google Scholar
• THOMAS MK, FRANCIS SH, CORBIN JD: Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem. (1990) 265:14964–14970.
   PubMed Web of Science ®Google Scholar
• FINK TL, FRANCIS SH, BEASLEY A, GRIMES KA, CORBIN JD: Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J. Biol. Chem. (1999) 274(49):34613–34620.
   PubMed Web of Science ®Google Scholar
• CORBIN JD, TURKO IV, BEASLEY A, FRANCIS SH: Phosphorylation of phosphodiesterase-5 by cyclic nucleotidedependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem. (2000) 267:2760–2767.
   PubMedGoogle Scholar
• MULLERSHAUSEN F, FRIEBE A, FEIL R et al.: Direct activation of PDE5 by cGMP: long-term effects within NO/ cGMP signaling. J. Cell Biol. (2003) 160(5):719–727.
   PubMed Web of Science ®Google Scholar
• RYBALKIN SD, RYBALKINA IG, SHIMIZU-ALBERGINE M, TANG XB, BEAVO J: PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. (2003) 22(3):469–478.
   PubMed Web of Science ®Google Scholar
• WALKER DK, ACKLAND MJ, JAMES GC et al.: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica (1999) 29(3):297–310.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD GJ, WILNER K, COLBURN W, HAUG-PIHALE G, ROUVIEX B: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br. J. Clin. Pharmacol. (2002) 53(Suppl. 1):21S-30S.
   Google Scholar
• MUIRHEAD GJ, FAULKNER S, HARNESS JA, TAUBEL J: The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br. J. Clin. Pharmacol. (2002) 53(Suppl. 1):37S-43S.
   Google Scholar
• MUIRHEAD GJ, RANCE DJ, WALKER DK, WASTALL P: Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br. J. Clin. Pharmacol. (2002) 53(Suppl. 1):13S–20S.
   PubMed Web of Science ®Google Scholar
• PADMA-NATHAN H, STECHER VJ, SWEENEY M et al.: Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology (2003) 62(3):400–403.
   PubMed Web of Science ®Google Scholar
• EARDLEY I, ELLIS P, BOOLELL M, WULFF M: Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br. J. Clin. Pharmacol. (2002) 53(Suppl. 1):61S–65S.
   PubMed Web of Science ®Google Scholar
• WARRINGTON JS, SHADER RI, VON MOLTKE LL, GREENBLATT DJ: In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab. Dispos. (2000) 28(4):392–397.
   PubMed Web of Science ®Google Scholar
• DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. (2000) 38(1):41–57.
   PubMed Web of Science ®Google Scholar
• HIGHLEYMAN L: Protease inhibitors and sildenafil (Viagra) should not be combined. Beta (1999) 12(2):3.
   Google Scholar
• WILNER K, LABOY L, LEBEL M: The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br. J. Clin. Pharmacol. (2002) 53(Suppl. 1):31S–36S.
   Google Scholar
• MUIRHEAD GJ, WULFF MB, FIELDING A, KLEINERMANS D, BUSS N: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. (2000) 50(2):99–107.
   PubMed Web of Science ®Google Scholar
• SADOVSKY R, MILLER T, MOSKOWITZ M, HACKETT G: Threeyear update of sildenafil citrate (Viagra) efficacy and safety. Int. J. Clin. Pract. (2001) 55(2):115–128.
   PubMed Web of Science ®Google Scholar
• PADMA-NATHAN H, EARDLEY I, KLONER RA, LATIES AM, MONTORSI F: A 4-year update on the safety of sildenafil citrate (Viagra). Urology (2002) 60(2 Suppl. 2):67–90.
   PubMed Web of Science ®Google Scholar
• SALONIA A, RIGATTI P, MONTORSI F: Sildenafil in erectile dysfunction: a critical review. Curr. Med. Res. Opin. (2003) 19(4):241–262.
   PubMed Web of Science ®Google Scholar
• CONTI CR, PEPINE CJ, SWEENEY M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol. (1999) 83(5A):29C–34C.
   PubMed Web of Science ®Google Scholar
• HERRMANN HC, CHANG G, KLUGHERZ BD, MAHONEY PD: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med. (2000) 342(22):1622–1626.
   PubMed Web of Science ®Google Scholar
• JACKSON G, BENJAMIN N, JACKSON N, ALLEN MJ: Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol. (1999) 83(5A):13C–20C.
   PubMed Web of Science ®Google Scholar
• KLONER RA, BROWN M, PRISANT LM, COLLINS M: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am. J. Hypertens. (2001) 14(1):70–73.
   PubMed Web of Science ®Google Scholar
• GUAY AT, PEREZ JB, JACOBSON J, NEWTON RA: Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J. Androl. (2001) 22(5):793–797.
   PubMed Web of Science ®Google Scholar
• LIM PH, MOORTHY P, BENTON KG: The clinical safety of viagra. Ann. NY Acad. Sci. (2002) 962:378–388.
   PubMed Web of Science ®Google Scholar
• HALCOX JP, NOUR KR, ZALOS G et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol. (2002) 40(7):1232–1240.
   PubMed Web of Science ®Google Scholar
• WEBSTER LJ, MICHELAKIS ED, DAVIS T, ARCHER SL: Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch. Intern. Med. (2004) 164(5):514–520.
   PubMed Web of Science ®Google Scholar
• DEBUSK RF, PEPINE CJ, GLASSER DB et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol. (2004) 93(2):147–153.
   PubMed Web of Science ®Google Scholar
• CROSBY R, METTEY A: A descriptive analysis of HIV risk behavior among men having sex with men attending a large sex resort. J. Acquir. Immune Defic. Syndr. (2004) 37(4):1496–1499.
   PubMed Web of Science ®Google Scholar
• LATIES AM, FRAUNFELDER FT: Ocular safety of Viagra, (sildenafil citrate). Trans. Am. Ophthalmol. Soc. (1999) 97:115–125;discussion 125–128.
   PubMedGoogle Scholar
• ZUSMAN RM, PRISANT LM, BROWN MJ: Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J. Hypertens. (2000) 18(12):1865–1869.
   PubMed Web of Science ®Google Scholar
• CARSON CC 3rd: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Curr. Urol. Rep. (2004) 5(6):449–450.
   Google Scholar
• BERKELS R, KLOTZ T, STICHT G, ENGLEMANN U, KLAUS W: Modulation of human platelet aggregation by the phosphodiesterase Type 5 inhibitor sildenafil. J. Cardiovasc. Pharmacol. (2001) 37(4):413–421.
   PubMed Web of Science ®Google Scholar
• PICKERING TG, SHEPHERD AM, PUDDEY I et al.: Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am. J. Hypertens. (2004) 17(12 Pt 1):1135–1142.
   PubMed Web of Science ®Google Scholar
• SOMMER F, ENGELMANN U: Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging (2004) 21(9):555–564.
   PubMed Web of Science ®Google Scholar
• SHABSIGH R, KAUFMAN JM, STEIDLE C, PADMA-NATHAN H: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (2004) 172(2):658–663.
   PubMed Web of Science ®Google Scholar
• GREENSTEIN A, MABJEESH NJ, SOFER M et al.: Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J. Urol. (2005) 173(2):530–532.
   PubMed Web of Science ®Google Scholar
• CREMERS B, BOHM M: Non erectile dysfunction application of sildenafil. Herz (2003) 28(4):325–333.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. (2002) 136(7):515–522.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 360(9337):895–900.
   PubMed Web of Science ®Google Scholar
• ATZ AM, LEFLER AK, FAIRBROTHER DL, UBER WE, BRADLEY SM: Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J. Thorac. Cardiovasc. Surg. (2002) 124(3):628–629.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED, TYMCHAK W, NOGA M et al.: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 108(17):2066–2069.
   PubMed Web of Science ®Google Scholar
• ROSENKRANZ S, DIET F, KARASCH T et al.: Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann. Intern. Med. (2003) 139(10):871–873.
   PubMed Web of Science ®Google Scholar
• ZHANG R, WANG Y, ZHANG L et al.: Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke (2002) 33(11):2675–2680.
   PubMed Web of Science ®Google Scholar
• BORTOLOTTI M, MARI C, LOPILATO C, PORRAZZO G, MIGLIOLI M: Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology (2000) 118(2):253–257.
   PubMed Web of Science ®Google Scholar
• PARK JW, MROWIETZ C, CHUNG N, JUNG F: Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study. Clin. Hemorheol. Microcirc. (2004) 31(3):173–183.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel on Impotence. JAMA (1993) 270:83–90.
   PubMed Web of Science ®Google Scholar
• Viagra® labelling information, US FDA submission Pfizer, (1997).
   Google Scholar